ITGAX and cancer: Despite the advance of cancer having a TME characterized by the anti-inflammatory phenotype, the increase in the expression of these markers in vitro (CD206, F4/80, CD163, CD11c) together with the increase in the number of macrophages infiltrated in the tissue exposed to the primary tumor reflects, in thesis, the ability to attenuate the growth or even regress the tumor.